Piper Jaffray Co. resumes coverage of Gilead Sciences Inc. (GILD:NSD) with an “Overweight” rating

Gilead Sciences Inc. News:

Gilead Sciences Inc is a leading biopharmaceutical company that has been at the forefront of developing innovative treatments for various diseases. The company’s portfolio of medicines includes treatments for HIV, hepatitis B and C, oncology, and more recently, COVID-19. However, the company’s first-quarter results for 2023 were lower than expected due to declining sales of its COVID-19 antiviral Veklury, which caused its shares to fall.

The company’s first-quarter profit was $1.37 per share, excluding items, compared to analysts’ expectations of $1.54 per share. This decline in profit was due to the decline in sales of Veklury, Gilead’s antiviral drug used in the treatment of COVID-19. Sales of Veklury declined more than anticipated, contributing to the lower-than-expected profits. This decline in Veklury sales is likely due to the ongoing rollout of vaccines, which has reduced the demand for COVID-19 treatments.

Despite the decline in Veklury sales, Gilead’s HIV portfolio performed well, with sales rising 13% to $4.19 billion. Biktarvy, a leading HIV treatment in Gilead’s portfolio, brought in $2.7 billion, exceeding Wall Street estimates of $2.53 billion. This growth in sales was driven by strong demand for Biktarvy in both the US and international markets.

Gilead left its full-year adjusted earnings forecast unchanged at $6.60 to $7.00 per share, indicating confidence in the company’s ability to perform well in the coming quarters. Gilead’s pipeline of drugs in development includes treatments for hepatitis B and C, oncology, and HIV. The company has also been exploring potential treatments for COVID-19, including its oral antiviral drug candidate, which is currently in clinical trials.

Gilead Sciences Inc Stock Forecast:

The average analyst target price for Gilead Sciences Inc (GILD:NSD) stock over the next 12 months is USD 85.94 and the average analyst rating is Buy. However, Stock Target Advisor‘s own analysis of the stock is Neutral, based on 7 positive signals and 7 negative signals. The stock price at the last closing was USD 83.55, with a change of -1.35% over the past week, +4.99% over the past month, and +35.66% over the last year.

Analysts Coverage Change:

Piper Jaffray Co. (RANK #16) resumes coverage of Gilead Sciences Inc. with an “Overweight” rating and a price target of $105 on the company’s stock.

GILD Ratings by Stock Target Advisor

Top Trending Stocks

AVG Analyst Rating STA Analysis
StockTargetAdvisor
Buy
StockTargetAdvisor
Slightly Bullish
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Slightly Bullish
StockTargetAdvisor
Buy
StockTargetAdvisor
Slightly Bullish
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Bullish
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Very Bullish
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Slightly Bullish
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Slightly Bullish
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Slightly Bullish
N/A
StockTargetAdvisor
Neutral
StockTargetAdvisor
Buy
StockTargetAdvisor
Bearish
Ad
Ad

Leave a Reply

Your email address will not be published. Required fields are marked *